Back to top
more

Conatus Pharmaceuticals Inc. (CNAT)

(Real Time Quote from BATS)

$0.35 USD

0.35
357,386

+0.02 (5.74%)

Updated Nov 22, 2019 03:08 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.62%
17.69%
9.40%
5.11%
2.01%
10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | C Growth | C Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CNAT

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNAT

Zacks Equity Research

Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes

Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.

PAHC SYK GWPH CNAT

Zacks Equity Research

Penumbra Enrolls First Patient for Study on Coronary Vessels

Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.

PEN SYK GWPH CNAT

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for September 10th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 10th

IAA DOOO CNAT AMBA

Zacks Equity Research

Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know

Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

CNAT

Zacks Equity Research

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

NVS PFE CNAT BGNE

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CNAT

Zacks Equity Research

Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNAT

Zacks Equity Research

Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

AMAG CNAT REGN ALXN GILD VRTX

Zacks Equity Research

Conatus' Emricasan Lags Primary Goal in Liver Function Study

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

PFE NVS CNAT ACOR

Zacks Equity Research

CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

CNAT ICPT GILD CBAY

Zacks Equity Research

Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNAT

Zacks Equity Research

Conatus Down More Than 60% in the Past 90 Days: Here's Why

Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

PFE AGN NVS CNAT

Zacks Equity Research

Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

PFE NVS CNAT PDLI

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CNAT

Zacks Equity Research

Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNAT

Zacks Equity Research

Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CNAT

Ekta Bagri

NASH Scorecard So Far This Year: A Look at the Hits & Misses

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

AGN NVS MRK CNAT VKTX GILD ICPT

Zacks Equity Research

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

Key highlights of the past week are multiple study failures and other pipeline updates.

CNAT GILD AMGN BIIB ALXN CYTK LXRX

Zacks Equity Research

Conatus (CNAT) Declines on Failure of NASH Fibrosis Study

Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

NVS CNAT ICPT GILD

Zacks Equity Research

Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

Conatus (CNAT) concentrates on the development of its lead candidate, emricasan, for treating patients with fibrosis or cirrhosis caused by NASH.

PFE NVS AGN CNAT

Zacks Equity Research

Implied Volatility Surging for Conatus (CNAT) Stock Options

Conatus (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.

CNAT

Zacks Equity Research

Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus

Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.

NVS PFE CNAT APYX

Zacks Equity Research

Conatus (CNAT) Completes Enrollment in Phase II NASH Study

Conatus (CNAT) completes enrollment in a phase IIb study on emricasan, being developed for the treatment of patients with fibrosis or cirrhosis caused by NASH.

NVS PFE CNAT GALT